Page 2737 - Cote clinical veterinary advisor dogs and cats 4th
P. 2737

Hyperadrenocorticism: Mitotane Induction for Adrenal Tumor 1425.e1



            Hyperadrenocorticism: Mitotane Induction for Adrenal Tumor
  VetBooks.ir

                                                    Mitotane@ 50-75 mg/kg divided BID
                                                               AND
                                                        Prednisone @ 0.2 mg/kg/d



                                                   Decreased appetite, vomiting, diarrhea,
                                                   listlessness, or water intake <60 mL/kg/d
                                                                OR
                                                          Maximum of 14 days



                                                         ACTH stimulation test





                 Post-ACTH at or above upper                Response ideal                  Post-ACTH lower half
                   half normal resting range                                                normal resting range


              Increase mitotane dose by 50 mg/kg/wk       Begin maintenance            Continue mitotane and prednisone
                   Continue prednisone as is           Mitotane: 75–100 mg/kg/wk               10–14 days
                Treat 10–14 days or until see signs     Prednisone: 0.2 mg/kg/d             OR until see signs that
                    that loading complete;                                              loading complete (e.g., reduced
                 repeat ACTH stim at that time                                          water intake); repeat ACTH stim
                                                                                                at that time

            Note: Ideal range is <30 nmol/L pre-and post-ACTH; normal resting range is 10–160 nmol/L.
            (From Rand J, Behrend E, Gunn-Moore D, Campbell-Ward M, editors: Clinical endocrinology of companion animals. New York: Wiley-Blackwell, 2013.)
            AUTHOR & EDITOR: Ellen N. Behrend, VMD, PhD, DACVIM















                                                                                                                      Clinical   Algorithms





















                                                      www.ExpertConsult.com
   2732   2733   2734   2735   2736   2737   2738   2739   2740   2741   2742